Psoriasis breakthrough: lower drug doses may work just as well
NCT ID NCT04340076
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether psoriasis patients who are stable on biologic drugs (IL17 or IL23 inhibitors) can safely reduce their dose without their skin condition getting worse. Researchers enrolled 244 adults with plaque psoriasis who had been on a normal dose for at least 6 months. Participants were randomly assigned to either continue their usual dose or gradually lower it. The goal was to see if dose reduction is as effective as standard care in preventing persistent flares.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL17 and IL23 inhibitors (Secukinumab, Ixekizumab, Brodalumab, Guselkumab)
What this could lead to
If successful, this could show that many psoriasis patients can safely lower their biologic dose without flare-ups, reducing side effects and costs.
What could go wrong
This is a completed Phase 4 study with 244 participants, so results are available but may not apply to all patients. Dose reduction might not work for everyone and could lead to disease flares.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Maria Middelares
Ghent, Belgium
-
AZ St Lucas
Ghent, Belgium
-
Amphia Hospital
Breda, Netherlands
-
Bravis hospital
Bergen op Zoom, Netherlands
-
CHU Liege
Liège, Belgium
-
Catharina hospital
Eindhoven, Netherlands
-
Dermatologie Maldegem
Maldegem, Belgium
-
Erasmus MC
Rotterdam, Netherlands
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Maastricht UMC
Maastricht, Netherlands
-
Máxima Medisch Centrum
Veldhoven, Netherlands
-
Radboudumc
Nijmegen, 6500HB, Netherlands
-
Slingeland hospital
Doetinchem, Netherlands
-
UCL Saint Luc
Leuven, Belgium
-
ULB Erasme
Brussels, Belgium
-
UMC Groningen
Groningen, Netherlands
-
UMC Utrecht
Utrecht, Netherlands
-
UZ Leuven
Leuven, Belgium
-
Ziekenhuisgroep Twente
Almelo, Netherlands